Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During Orthopedic Surgeries in Egyptian Patients.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cefazolin 2 g Infusion, Cefazolin 2 GM Injection.
- Who it may be relevant to
- Registry conditions: Surgical Site Infection (SSI). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
A randomized controlled trial on adults who underwent orthopedic surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population. Eligible patients will be randomized in a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).
Interventions
- Drug Cefazolin 2 g Infusion
Intraoperative continuous infusion (CI) of cefazolin - Drug Cefazolin 2 GM Injection
Administration of cefazolin 2 gm 30 minutes pre-surgery
Primary outcome measures
- Incidence of surgical site infection [Time frame: within 90 days after surgery.]
Eligibility criteria
Inclusion criteria
- Orthopaedic surgical ward patients who underwent major surgery.
Exclusion criteria
- Patients who require reoperation within 30 days.
- Immunosuppressant patients.
- Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
- Pregnancy or breastfeeding.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07655596 · 1803062025